IL1B and Alzheimer disease: In transgenic mice with AD plaque development, daily administration of azeliragon (10 mg/kg via intraperitoneal injection or 20 mg/kg orally) significantly reduced inflammatory markers (TNF-α, TGF-β, and IL-1), amyloid deposition in the central nervous system, and improved cognitive function [48].